BR112016016202A2 - Construtos de direcionamento de receptores e uso dos mesmos - Google Patents
Construtos de direcionamento de receptores e uso dos mesmosInfo
- Publication number
- BR112016016202A2 BR112016016202A2 BR112016016202A BR112016016202A BR112016016202A2 BR 112016016202 A2 BR112016016202 A2 BR 112016016202A2 BR 112016016202 A BR112016016202 A BR 112016016202A BR 112016016202 A BR112016016202 A BR 112016016202A BR 112016016202 A2 BR112016016202 A2 BR 112016016202A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- disclosed
- targeting constructs
- delivering
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
CONSTRUTOS DE DIRECIONAMENTO DE RECEPTORES E USO DOS MESMOS. Divulgadas neste documento são moléculas de distribuição de droga que compreendem um ligante que tem como alvo uma molécula da superfície celular; um domínio de penetração da membrana; e um domínio de ligação de carga útil; e composições farmacêuticas compreendendo os mesmos. Também são divulgados os métodos de tratamento de câncer, inibição da progressão do câncer, prevenção de metástases do câncer e a distribuição de um composto terapêutico ao cérebro em um sujeito com necessidade dos mesmos, os métodos compreendendo a identificação de um sujeito com esta necessidade; fornecimento de uma composição compreendendo a molécula de distribuição de droga, como divulgado neste documento; e a distribuição de uma quantidade eficaz da composição ao sujeito.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461928903P | 2014-01-17 | 2014-01-17 | |
PCT/US2015/011870 WO2015109264A1 (en) | 2014-01-17 | 2015-01-16 | Receptor targeting constructs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016016202A2 true BR112016016202A2 (pt) | 2017-09-19 |
Family
ID=53543519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016016202A BR112016016202A2 (pt) | 2014-01-17 | 2015-01-16 | Construtos de direcionamento de receptores e uso dos mesmos |
Country Status (14)
Country | Link |
---|---|
US (3) | US10183078B2 (pt) |
EP (2) | EP3791889B1 (pt) |
JP (2) | JP6608370B2 (pt) |
KR (1) | KR102434541B1 (pt) |
CN (1) | CN106413738B (pt) |
AU (2) | AU2015206271B2 (pt) |
BR (1) | BR112016016202A2 (pt) |
CA (1) | CA2935404A1 (pt) |
HK (1) | HK1231385A1 (pt) |
IL (1) | IL246668B (pt) |
MX (1) | MX2016009284A (pt) |
RU (1) | RU2682335C2 (pt) |
WO (1) | WO2015109264A1 (pt) |
ZA (1) | ZA201605237B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
PL2880160T3 (pl) | 2012-08-03 | 2019-03-29 | Cedars-Sinai Medical Center | Izolowanie wzmacniających transport mutantów białka dostarczającego lek |
US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
MX2016009284A (es) | 2014-01-17 | 2016-10-07 | Cedars Sinai Medical Center | Construcciones dirigidas a receptor y sus usos. |
US9850293B2 (en) | 2014-04-04 | 2017-12-26 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle |
CA3039040A1 (en) * | 2016-10-03 | 2018-04-12 | Eos Biosciences, Inc. | Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles |
CN108865147B (zh) * | 2018-06-01 | 2021-05-18 | 福州大学 | 一种埃罗替尼保护的铂银纳米簇及其制备方法 |
RU2688422C1 (ru) * | 2018-06-07 | 2019-05-21 | Светлана Александровна Ермолаева | Рекомбинантный интерналин В 321, полученный с помощью штамма Escherichia coli |
WO2020028562A1 (en) * | 2018-07-31 | 2020-02-06 | Loma Linda University | Snail sirna-loaded mesoporous silica nanoparticles |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
CA2391534A1 (en) | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
US6855135B2 (en) | 2000-11-29 | 2005-02-15 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
AU2002240201A1 (en) | 2001-02-02 | 2002-08-19 | Yale University | Peptides for facilitating composite receptor expression and translocation of macromolecules |
WO2002094318A1 (en) | 2001-05-18 | 2002-11-28 | University Of Southern California | Vector for targeted delivery to cells |
WO2003004021A1 (en) | 2001-07-02 | 2003-01-16 | Technion Research And Development Foundation Ltd. | Method for the preparation of selectively-substituted corroles and new substituted corroles |
SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
EP1374812A1 (en) | 2002-06-28 | 2004-01-02 | Biopol Co., Ltd. | Multilayered microporous foam dressing and method for manufacturing the same |
US7329638B2 (en) | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
US7205387B2 (en) | 2003-08-28 | 2007-04-17 | Agency For Science, Technology And Research | Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist |
US20050096502A1 (en) | 2003-10-29 | 2005-05-05 | Khalili Theodore M. | Robotic surgical device |
US20060014712A1 (en) | 2004-05-30 | 2006-01-19 | Cemines, Inc. | Controlled delivery of therapeutic compounds |
US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
WO2007137117A2 (en) | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
AU2008293376B2 (en) | 2007-08-28 | 2013-07-11 | Technion Research & Development Foundation Ltd. | Transition metal complexes of corroles for preventing cardiovascular diseases or disorders |
WO2009151539A1 (en) * | 2008-05-24 | 2009-12-17 | Sirnaomics, Inc. | COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS |
US10036099B2 (en) | 2008-08-07 | 2018-07-31 | Slt Technologies, Inc. | Process for large-scale ammonothermal manufacturing of gallium nitride boules |
WO2010078517A2 (en) * | 2008-12-31 | 2010-07-08 | Sirnaomics, Inc. | Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer |
WO2010085665A2 (en) * | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
CN102625697A (zh) | 2009-09-01 | 2012-08-01 | 西北大学 | 使用经寡核苷酸修饰的纳米颗粒作为载体来递送治疗剂 |
WO2011094335A2 (en) | 2010-01-26 | 2011-08-04 | Yale University | Microrna signatures predicting responsiveness to anti-her2 therapy |
AU2013243946A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
US10070994B2 (en) | 2012-05-22 | 2018-09-11 | Smith & Nephew Plc | Apparatuses and methods for wound therapy |
PL2880160T3 (pl) | 2012-08-03 | 2019-03-29 | Cedars-Sinai Medical Center | Izolowanie wzmacniających transport mutantów białka dostarczającego lek |
US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
MX2016009284A (es) | 2014-01-17 | 2016-10-07 | Cedars Sinai Medical Center | Construcciones dirigidas a receptor y sus usos. |
US9850293B2 (en) | 2014-04-04 | 2017-12-26 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle |
EP3186378A1 (en) | 2014-08-27 | 2017-07-05 | Peptimed, Inc. | Anti-tumor compositions and methods |
KR20190013929A (ko) | 2016-05-27 | 2019-02-11 | 세다르스-신나이 메디칼 센터 | 약물-전달 나노입자 및 약물 내성암에 대한 치료 |
CA3039040A1 (en) | 2016-10-03 | 2018-04-12 | Eos Biosciences, Inc. | Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles |
US20210077575A1 (en) | 2018-01-02 | 2021-03-18 | Cedars-Sinai Medical Center | Nanoparticles for the targeted delivery of therapeutic polypeptides |
-
2015
- 2015-01-16 MX MX2016009284A patent/MX2016009284A/es unknown
- 2015-01-16 KR KR1020167020838A patent/KR102434541B1/ko active IP Right Grant
- 2015-01-16 EP EP20182924.9A patent/EP3791889B1/en active Active
- 2015-01-16 JP JP2016546449A patent/JP6608370B2/ja active Active
- 2015-01-16 EP EP15737653.4A patent/EP3096773B1/en active Active
- 2015-01-16 CN CN201580004623.9A patent/CN106413738B/zh active Active
- 2015-01-16 RU RU2016124731A patent/RU2682335C2/ru active
- 2015-01-16 BR BR112016016202A patent/BR112016016202A2/pt not_active Application Discontinuation
- 2015-01-16 US US15/112,162 patent/US10183078B2/en active Active
- 2015-01-16 CA CA2935404A patent/CA2935404A1/en active Pending
- 2015-01-16 AU AU2015206271A patent/AU2015206271B2/en active Active
- 2015-01-16 WO PCT/US2015/011870 patent/WO2015109264A1/en active Application Filing
-
2016
- 2016-07-07 IL IL246668A patent/IL246668B/en unknown
- 2016-07-28 ZA ZA2016/05237A patent/ZA201605237B/en unknown
-
2017
- 2017-05-19 HK HK17105050.7A patent/HK1231385A1/zh unknown
-
2018
- 2018-11-20 US US16/197,240 patent/US11369687B2/en active Active
-
2019
- 2019-10-23 JP JP2019192818A patent/JP2020033365A/ja active Pending
-
2020
- 2020-05-25 AU AU2020203434A patent/AU2020203434B2/en active Active
-
2022
- 2022-05-23 US US17/751,366 patent/US20220362389A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3096773A4 (en) | 2018-02-21 |
US20190142962A1 (en) | 2019-05-16 |
RU2016124731A (ru) | 2018-02-22 |
AU2020203434A1 (en) | 2020-06-11 |
AU2020203434B2 (en) | 2023-02-09 |
MX2016009284A (es) | 2016-10-07 |
CA2935404A1 (en) | 2015-07-23 |
US20220362389A1 (en) | 2022-11-17 |
KR102434541B1 (ko) | 2022-08-19 |
EP3096773A1 (en) | 2016-11-30 |
IL246668B (en) | 2022-02-01 |
CN106413738B (zh) | 2020-12-29 |
KR20160108391A (ko) | 2016-09-19 |
HK1231385A1 (zh) | 2017-12-22 |
EP3791889B1 (en) | 2024-02-21 |
EP3791889A1 (en) | 2021-03-17 |
EP3096773B1 (en) | 2020-07-01 |
AU2015206271A1 (en) | 2016-07-07 |
US10183078B2 (en) | 2019-01-22 |
ZA201605237B (en) | 2019-04-24 |
WO2015109264A1 (en) | 2015-07-23 |
CN106413738A (zh) | 2017-02-15 |
US20160331840A1 (en) | 2016-11-17 |
IL246668A0 (en) | 2016-08-31 |
RU2016124731A3 (pt) | 2018-09-18 |
JP6608370B2 (ja) | 2019-11-20 |
JP2017508724A (ja) | 2017-03-30 |
US11369687B2 (en) | 2022-06-28 |
JP2020033365A (ja) | 2020-03-05 |
RU2682335C2 (ru) | 2019-03-19 |
AU2015206271B2 (en) | 2020-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016016202A2 (pt) | Construtos de direcionamento de receptores e uso dos mesmos | |
CY1124606T1 (el) | Στοχευμενη χορηγηση φαρμακευτικων ουσiων που περιεχουν τριτοταγη αμινη | |
MX2023008041A (es) | Composiciones de acido nucleico-polipeptido y sus aplicaciones. | |
MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
BR122021004223A8 (pt) | Molécula de anticorpo, composição, sequência de nucleotídeo, vetor, molécula de anticorpo e uso de uma molécula de anticorpo | |
BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
BR112017012342A2 (pt) | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos | |
BR112016022553A2 (pt) | Compostos e métodos para entrega transmembrana de moléculas? | |
BR112015009752A2 (pt) | conjugados de anticorpo/fármaco e métodos de uso | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
BR112012020558A2 (pt) | moduladores do receptor de androgênio e seus usos | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
MX2019013690A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
BR112019024747A2 (pt) | formulações de dose fixa | |
BR112017012482A2 (pt) | copolímero estático, composição, uso de um copolímero, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção do copolímero. | |
PH12019502692A1 (en) | Anti-cancer combination therapy | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
BR112017016503A2 (pt) | conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo | |
MX2020006116A (es) | Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t. | |
BR112015033053A2 (pt) | método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit | |
JO3668B1 (ar) | مركبات بلاديينوليد البيريدين وطرق استعمالها |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |